Portal de investigación
Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain real world evidence (RWE) data. GeminiS study
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Tamayo, RR
- Herraiz, MA
- Garcia, AD
- Suarez-Llanos, JLSM
- Soler, JA
- Guinon, AG
- Lopez, SG
- Guia, A
- Farre, CL
- Pardo, MG
- Mateos, MV
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 2152-2650, 2152-2669
- Tipo:
- Meeting Abstract
- Páginas:
- 147-147
- Factor de Impacto:
- 0,819 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Clinical Lymphoma Myeloma & Leukemia CIG MEDIA GROUP, LP
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- monoclonal antibody; real-world evidence; Relapsed Refractory MM
Campos de Estudio
Cita
Tamayo,RR,Herraiz,MA,Garcia,AD,Suarez,JLSM,Soler,JA,Guinon,AG,Lopez,SG et al. Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain real world evidence (RWE) data. GeminiS study. 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931:CIG MEDIA GROUP, LP. 2019 p.p. 147-147.